Pharmacogenomics: from bedside to clinical practice

被引：49

作者：

Marsh, S ^{[1
]}

McLeod, HL ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA

来源：

HUMAN MOLECULAR GENETICS | 2006年 / 15卷

关键词：

D O I：

10.1093/hmg/ddl087

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The field of pharmacogenomics has seen some exciting advances in the recent past. The Human Genome Project and International HapMap projects have uncovered a wealth of information for researchers. The discovery of clinically predictive genotypes (e.g. UGT1A1*28, TYMS TSER), haplotypes (e.g. VKORC1 Haplotype A) and somatic mutations (e.g. epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice. This review describes some of the recent advances in pharmacogenomics research.

引用

页码：R89 / R93

页数：5

共 46 条

[1]

Ando Y, 2000, CANCER RES, V60, P6921

[2]

[Anonymous], BANDOLIER EXTRA

[3] The pharmacology and management of the vitamin K antagonists [J].

Ansell, J ;

Hirsh, J ;

Poller, L ;

Bussey, H ;

Jacobson, A ;

Hylek, E .

CHEST, 2004, 126 (03) :204S-233S

[4] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].

Bell, DW ;

Lynch, TJ ;

Haserlat, SM ;

Harris, PL ;

Okimoto, RA ;

Brannigan, BW ;

Sgroi, DC ;

Muir, B ;

Riemenschneider, MJ ;

Iacona, RB ;

Krebs, AD ;

Johnson, DH ;

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Fukuoka, M ;

Kris, MG ;

Baselga, J ;

Ochs, JS ;

Haber, DA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092

[5] Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism? [J].

Beutler, E ;

Gelbart, T ;

Demina, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8170-8174

[6]

CHANG C, 2006, FILM COMMENT, V42, P17

[7] Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes [J].

Cheng, Q ;

Yang, WJ ;

Raimondi, SC ;

Pui, CH ;

Relling, MV ;

Evans, WE .

NATURE GENETICS, 2005, 37 (08) :878-882

[8]

Chenhsu RY, 2000, ANN PHARMACOTHER, V34, P1395

[9] Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler-Najjar type I disease [J].

Ciotti, M ;

Chen, F ;

Rubaltelli, FF ;

Owens, IS .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1998, 1407 (01) :40-50

[10] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].

D'Andrea, G ;

D'Ambrosio, RL ;

Di Perna, P ;

Chetta, M ;

Santacroce, R ;

Brancaccio, V ;

Grandone, E ;

Margaglione, M .

BLOOD, 2005, 105 (02) :645-649

← 1 2 3 4 5 →